Morgan Stanley analyst Jeffrey Hung maintained a Hold rating on Prelude Therapeutics (PRLD – Research Report) today and set a price target of $10.00. The company’s shares opened today at $7.98.
According to TipRanks, Hung is a 5-star analyst with an average return of 23.8% and a 56.52% success rate. Hung covers the Healthcare sector, focusing on stocks such as Rubius Therapeutics, Prelude Therapeutics, and Neurocrine.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Prelude Therapeutics with a $13.00 average price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $16.49 and a one-year low of $3.87. Currently, Prelude Therapeutics has an average volume of 68.94K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need.
Read More on PRLD:
